All In Biotech

Drug Trial Radar · NCT04150029

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

90

Actual

Start

Sep 1, 2020

Primary completion

Oct 25, 2024

Study completion Oct 25, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • MBG453Drug

    Solution for intravenous infusion

  • VenetoclaxDrug

    Tablet for oral administration

  • AzacitidineDrug

    Solution for subcutaneous injection or intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLT)(Safety run-in Patients Only)Time frame: From Cycle 1 Day 8 to end of Cycle 2; Cycle =28 Days
  2. Percentage of Participants Achieving Complete Remission (CR) (CR Rate)Time frame: approx. 31 months

Locations

28 sites in 10 countries. Site status is shown where the registry gives one.

  • 25Uni of Alabama at Birmingham

    Birmingham, Alabama

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Uni Of Iowa Hospitals And Clinics

    Iowa City, Iowa

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Memorial Sloan Kettering

    New York, New York

  • Weill Cornell Medicine NY-Presb

    New York, New York

  • Levine Cancer Insitute Carolinas Healthcare System

    Charlotte, North Carolina

  • Duke Univ Medical Center

    Durham, North Carolina

  • Chattanooga Onc And Hem Assoc PC

    Chattanooga, Tennessee

  • MD Anderson Cancer Center University of Texas

    Houston, Texas

  • Huntsman Cancer Institute Univ of Utah

    Salt Lake City, Utah

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Leipzig, Saxony, Germany

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Fukushima, Fukushima, Japan

  • Novartis Investigative Site

    Yamagata, Yamagata, Japan

  • Novartis Investigative Site

    Seoul, Seocho gu, South Korea

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Kaohsiung City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.